Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ...

Introduction Body image disturbance (BID) is a complex construct that includes cognitive-affective, perceptual and behavioural characteristics, influencing how people perceive and feel about their ...

Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that the University of ...

AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide ...

Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), today announced that it will ...

My experiences have demonstrated that business development combined with market analysis is the most powerful pairing for ...